Aurobindo Pharma plans to raise $300 million via QIP: Report

09 Oct 2015 Evaluate

Aurobindo Pharma, one of the leading Indian pharmaceutical research companies, is reportedly planning to launch a qualified institutional placement (QIP) issue to mop up around $300 million. The company has hired Citigroup and Bank of America-Merrill Lynch as bankers for the share sale which is expected to take place within a couple of weeks. The investment bankers have already launched soft marketing of the deal and are ready to launch the issue, depending on market conditions.

Aurobindo Pharma, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1161.85 -14.80 (-1.26%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×